原发性阴道癌治疗的研究进展

doi:10.12280/gjszjk.20220518

摘要/Abstract

摘要：

原发性阴道癌是一种罕见的妇科恶性肿瘤，且是目前唯一一种在美国国立综合癌症网络中没有临床实践指南的女性生殖系统肿瘤。对于原发性阴道癌的治疗，目前尚未提出最佳的治疗方案，个体化的放化疗仍然是该病的主要治疗方法，其改善了疾病的局部控制率和总体生存率。早期原发性阴道癌通常采用手术或放疗，而对于晚期原发性阴道癌，同步放化疗成为了一种有效的替代治疗。与其他恶性肿瘤一样，原发性阴道癌诊断时的临床分期是重要的预后因素，而年龄、病灶大小和组织学类型等也会影响生存结局，其中免疫治疗有望成为改善原发性阴道癌预后的新策略。综述原发性阴道癌的手术方法、放疗、放化疗和免疫治疗及其预后的最新进展。

关键词: 阴道肿瘤, 放射疗法, 化放疗, 免疫疗法, 妇科外科手术

Abstract:

Primary vaginal cancer is a rare gynecologic malignancy, which is the only female reproductive system cancer without clinical practice guidelines in the National Comprehensive Cancer Network. For the treatment of primary vaginal cancer, the best treatment plan has not been proposed yet. The individualized radiotherapy and chemotherapy are still the main treatment methods for vaginal cancer, which may improve the local control rate and overall survival rate. The primary vaginal cancer at early stage usually adopts surgery or radiotherapy, while the vaginal cancer at the advanced stage may adopt the concurrent chemoradiotherapy as an effective alternative treatment. As with the other malignancies, the clinical stage at diagnosis of primary vaginal cancer is the most important prognostic factor, while age, lesion size and histologic type can also affect survival outcomes. Interestingly, the immunotherapy may be a new strategy to improve the prognosis of vaginal cancer. This paper review the treatment methods of primary vaginal cancer, including surgical approaches, radiotherapy, radiochemotherapy and immunotherapy, as well as the respective prognoses.

Key words: Vaginal neoplasms, Radiotherapy, Chemoradiotherapy, Immunotherapy, Gynecologic surgical procedures

袁雨钦, 李红英. 原发性阴道癌治疗的研究进展[J]. 国际生殖健康/计划生育杂志, 2023, 42(2): 172-176.

YUAN Yu-qin, LI Hong-ying. Research Progress in Treatment of Primary Vaginal Cancer[J]. Journal of International Reproductive Health/Family Planning, 2023, 42(2): 172-176.

参考文献 36

[1]	Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3):145-164. doi: 10.3322/caac.21601. doi: 10.3322/caac.21601 URL
[2]	Rajaram S, Maheshwari A, Srivastava A. Staging for vaginal cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2015, 29(6):822-832. doi: 10.1016/j.bpobgyn.2015.01.006. doi: 10.1016/j.bpobgyn.2015.01.006 pmid: 25847318
[3]	Palma Dos Reis C, Correia L, Jorge AF, et al. Primary vaginal cancer associated with HPV 68: A case report of an unusual presentation[J]. Int J Gynaecol Obstet, 2021, 152(2):262-263. doi: 10.1002/ijgo.13361. doi: 10.1002/ijgo.13361 URL
[4]	Rasmussen CL, Bertoli HK, Sand FL, et al. The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: A systematic review[J]. Acta Obstet Gynecol Scand, 2021, 100(12):2144-2156. doi: 10.1111/aogs.14260. doi: 10.1111/aogs.14260 URL
[5]	Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155(Suppl 1):19-27. doi: 10.1002/ijgo.13867. doi: 10.1002/ijgo.13867
[6]	Yang J, Delara R, Magrina J, et al. Management and outcomes of primary vaginal Cancer[J]. Gynecol Oncol, 2020, 159(2):456-463. doi: 10.1016/j.ygyno.2020.08.036. doi: 10.1016/j.ygyno.2020.08.036 pmid: 32972784
[7]	Jhingran A. Updates in the treatment of vaginal cancer[J]. Int J Gynecol Cancer, 2022, 32(3):344-351. doi: 10.1136/ijgc-2021-002517. doi: 10.1136/ijgc-2021-002517 pmid: 35256422
[8]	Kulkarni A, Dogra N, Zigras T. Innovations in the Management of Vaginal Cancer[J]. Curr Oncol, 2022, 29(5):3082-3092. doi: 10.3390/curroncol29050250. doi: 10.3390/curroncol29050250 pmid: 35621640
[9]	Goodman CD, Mendez LC, Velker V, et al. 3D image-guided interstitial brachytherapy for primary vaginal cancer: A multi-institutional experience[J]. Gynecol Oncol, 2021, 160(1):134-139. doi: 10.1016/j.ygyno.2020.10.021. doi: 10.1016/j.ygyno.2020.10.021 pmid: 33162177
[10]	Meixner E, Arians N, Bougatf N, et al. Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors[J]. Tumori, 2023, 109(1):112-120. doi: 10.1177/03008916211056369. doi: 10.1177/03008916211056369 URL
[11]	How JA, Jazaeri AA, Soliman PT, et al. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase Ⅱ basket trial[J]. Sci Rep, 2021, 11(1):3667. doi: 10.1038/s41598-021-83317-7. doi: 10.1038/s41598-021-83317-7
[12]	Zhou W, Yue Y, Pei D. Survival benefit of vaginectomy compared to local tumor excision in women with FIGO stage Ⅰ and Ⅱ primary vaginal carcinoma: a SEER study[J]. Arch Gynecol Obstet, 2020, 302(6):1429-1439. doi: 10.1007/s00404-020-05737-6. doi: 10.1007/s00404-020-05737-6
[13]	Hiniker SM, Roux A, Murphy JD, et al. Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes[J]. Gynecol Oncol, 2013, 131(2):380-385. doi: 10.1016/j.ygyno.2013.08.012. doi: 10.1016/j.ygyno.2013.08.012 pmid: 23954572
[14]	Khadraoui W, Zeybek B, Mutlu L, et al. Robotic type ⅡB posterior exenteration for recurrent vaginal cancer[J]. Gynecol Oncol, 2019, 155(2):384-385. doi: 10.1016/j.ygyno.2019.07.014. doi: S0090-8258(19)31403-9 pmid: 31345607
[15]	Yao F, Zhao W, Chen G, et al. Comparison of laparoscopic peritoneal vaginoplasty and sigmoid colon vaginoplasty performed during radical surgery for primary vaginal carcinoma[J]. World J Surg Oncol, 2014, 12:302. doi: 10.1186/1477-7819-12-302. doi: 10.1186/1477-7819-12-302 pmid: 25266567
[16]	Kirkbride P, Fyles A, Rawlings GA, et al. Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989)[J]. Gynecol Oncol, 1995, 56(3):435-443. doi: 10.1006/gyno.1995.1077. doi: 10.1006/gyno.1995.1077 pmid: 7705681
[17]	Gadducci A, Fabrini MG, Lanfredini N, et al. Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors[J]. Crit Rev Oncol Hematol, 2015, 93(3):211-224. doi: 10.1016/j.critrevonc.2014.09.002. doi: 10.1016/j.critrevonc.2014.09.002 pmid: 25476235
[18]	Westerveld H, Nesvacil N, Fokdal L, et al. Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer[J]. Lancet Oncol, 2020, 21(3):e157-e167. doi: 10.1016/S1470-2045(19)30855-1. doi: 10.1016/S1470-2045(19)30855-1 pmid: 32135119
[19]	Liao Y, Tatebe K, Barry P, et al. A novel use of 3D-printed template in vaginal HDR brachytherapy[J]. Brachytherapy, 2022, 21(2):238-243. doi: 10.1016/j.brachy.2021.09.005. doi: 10.1016/j.brachy.2021.09.005 URL
[20]	Contreras J, Srivastava A, Chundury A, et al. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer[J]. Int J Gynecol Cancer, 2020, 30(8):1157-1161. doi: 10.1136/ijgc-2020-001412. doi: 10.1136/ijgc-2020-001412 pmid: 32527770
[21]	Bejar FG, Oaknin A, Williamson C, et al. Novel Therapies in Gynecologic Cancer[J]. Am Soc Clin Oncol Educ Book, 2022, 42:1-17. doi: 10.1200/EDBK_351294. doi: 10.1200/EDBK_351294 pmid: 35594502
[22]	Dalrymple JL, Russell AH, Lee SW, et al. Chemoradiation for primary invasive squamous carcinoma of the vagina[J]. Int J Gynecol Cancer, 2004, 14(1):110-117. doi: 10.1111/j.1048-891x.2004.014066.x. doi: 10.1111/j.1048-891x.2004.014066.x pmid: 14764038
[23]	Samant R, Lau B, E C, et al. Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum[J]. Int J Radiat Oncol Biol Phys, 2007, 69(3):746-750. doi: 10.1016/j.ijrobp.2007.04.015. doi: 10.1016/j.ijrobp.2007.04.015 URL
[24]	Rajagopalan MS, Xu KM, Lin JF, et al. Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study[J]. Gynecol Oncol, 2014, 135(3):495-502. doi: 10.1016/j.ygyno.2014.09.018. doi: 10.1016/j.ygyno.2014.09.018 pmid: 25281493
[25]	Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy[J]. Cancer Discov, 2018, 8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. doi: 10.1158/2159-8290.CD-18-0367 pmid: 30115704
[26]	Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase Ⅰ/Ⅱ CheckMate 358 Trial[J]. J Clin Oncol, 2019, 37(31):2825-2834. doi: 10.1200/JCO.19.00739. doi: 10.1200/JCO.19.00739 pmid: 31487218
[27]	Wang Y, Deng W, Li N, et al. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions[J]. Front Pharmacol, 2018, 9:185. doi: 10.3389/fphar.2018.00185. doi: 10.3389/fphar.2018.00185 pmid: 29556198
[28]	Hacker NF, Eifel PJ, van der Velden J. Cancer of the vagina[J]. Int J Gynaecol Obstet, 2015, 131(Suppl 2):S84-S87. doi: 10.1016/j.ijgo.2015.06.003. doi: 10.1016/j.ijgo.2015.06.003 URL
[29]	Egger EK, Ralser DJ, Lindner K, et al. Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report[J]. Front Immunol, 2021, 12:686879. doi: 10.3389/fimmu.2021.686879. doi: 10.3389/fimmu.2021.686879 URL
[30]	Tanwar RK, Saxena B, Ali S, et al. Primary malignant melanoma of the vagina: Report of two rare cases[J]. J Cancer Res Ther, 2018, 14(6):1439-1441. doi: 10.4103/jcrt.JCRT_1335_16. doi: 10.4103/jcrt.JCRT_1335_16 pmid: 30488873
[31]	Kalampokas E, Kalampokas T, Damaskos C. Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature[J]. In Vivo, 2017, 31(1):133-139. doi: 10.21873/invivo.11036. doi: 10.21873/invivo.11036 pmid: 28064232
[32]	Wohlmuth C, Wohlmuth-Wieser I, Laframboise S. Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina[J]. J Low Genit Tract Dis, 2021, 25(2):146-151. doi: 10.1097/LGT.0000000000000583. doi: 10.1097/LGT.0000000000000583 URL
[33]	Kühn F, Dieterich M, Klar E, et al. Primary Malignant Vaginal Melanoma-Case Report and Review of the Literature[J]. Geburtshilfe Frauenheilkd, 2012, 72(8):740-743. doi: 10.1055/s-0032-1315006. doi: 10.1055/s-0032-1315006 URL
[34]	Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature[J]. Am J Obstet Gynecol, 1998, 178(6):1177-1184. doi: 10.1016/s0002-9378(98)70320-5. doi: 10.1016/s0002-9378(98)70320-5 pmid: 9662299
[35]	Bisogno G, Compostella A, Ferrari A, et al. Rhabdomyosarcoma in adolescents: a report from the AIEOP Soft Tissue Sarcoma Committee[J]. Cancer, 2012, 118(3):821-827. doi: 10.1002/cncr.26355. doi: 10.1002/cncr.26355 pmid: 21751206
[36]	Yuan G, Yao H, Li X, et al. Stage 1 embryonal rhabdomyosarcoma of the female genital tract: a retrospective clinical study of nine cases[J]. World J Surg Oncol, 2017, 15(1):42. doi: 10.1186/s12957-017-1110-y. doi: 10.1186/s12957-017-1110-y pmid: 28173865